New drug litfulo tracked in 3,000 patients for hair loss treatment
NCT ID NCT07152119
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is monitoring the safety and effectiveness of Litfulo (Ritlecitinib) in 3,000 people with severe alopecia areata, a condition causing patchy hair loss. Participants take the drug as prescribed in real-world clinics across Korea. Researchers will track side effects and hair regrowth over 48 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Litfulo (Ritlecitinib)
What this could lead to
If successful, this study could confirm that Litfulo is a safe and effective treatment for severe alopecia areata in adults and teens.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. Side effects are possible, and not everyone may respond to treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE ALOPECIA AREATA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer
RECRUITINGSeoul, South Korea